BioPharmaceutical

At a recent conference, executives from Boehringer and Amgen laid out their expectations for the future of obesity and how they intend to navigate the changes.

The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

As talks continue on the EU pharmaceutical legislative reform proposals, drug firms may have to wait some time before they find out what the future periods of regulatory data protection and orphan market exclusivity will be.

Experts working in the advanced therapy sector tell In Vivo how novel solutions can empower cell and gene therapy manufacturers to reduce costs, improve scalability and optimize their processes – improving the clinical profile and commercial viability of products.

Dreams of a future with early curative treatments drives wave of drug development in pre-surgical and perioperative treatment in many tumor types.

Hikma says that its acquisition of Xellia’s finished dosage form business and a key contract manufacturing agreement in generics have kept its business on track to meet its full-year forecasts.

Running from 11-14 November, the fifth annual Global Biosimilars Week awareness campaign has been launched by the IGBA, with the international off-patent association this year focusing on advancing access.

Medixci’s Nick Williams told attendees at BIO-Europe that it was a shame that promising biotechs head to the NASDAQ as soon as possible. He and called for a change in culture from investors and for them to back the continent’s start-ups with proper funding.

After a “solid start to the year”, Organon has delivered on analyst expectations with its third quarter results, despite ongoing questions surrounding future growth and market penetration of key compounds. Meanwhile, the firm’s filing for a biosimilar rival to Prolia/Xgeva has been accepted by the FDA.